Clinical trial · Interventional
Study Looking at Biomarkers in Ovarian Cancer
Biomarker Discovery Project in High Grade Serous Ovarian Cancer
NCT03419689CI-TRIAL-00098365recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ascites Collection | Procedure | — | UNRESOLVED |
| Blood sample collection | Procedure | — | UNRESOLVED |
| Fluid Collection | Procedure | — | UNRESOLVED |
| Tumour tissue collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sample Collection
- description
- The following samples may be collected during the study: * Tumour tissue samples * Blood samples * Ascites samples * Other fluids requiring drainage
- interventionNames
- Procedure: Tumour tissue collection
- Procedure: Blood sample collection
- Procedure: Ascites Collection
- Procedure: Fluid Collection
Primary outcomes (4)
- measure
- Genomic and immune signatures in terms of progression free survival
- timeFrame
- 10 years
- description
- Short term (1-2 years) versus long term (5-10 years) survival
- measure
- Genomic and immune signatures in terms of overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of stage III or IV high grade serous ovarian, tubal or primary peritoneal cancer. * Must be 18 years of age or older. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Have a life expectancy greater than or equal to 6 months. * Able to provide adequate informed consent. * Willing to undergo blood or fluid collection and tumour biopsy * Patients enrolled at the time of surgery must agree to have part of their tumour used for the purpose of the study. * Archival tissue must be available for patients that are enrolled at the time of progression. Exclusion Criteria: * Must not have early stage (I and II) high grade serous, tubal or primary peritoneal cancer. * Must not have other tumour histology other than high grade serous. * Must not have contraindication to tumour biopsy and/or blood sampling.
References
Publications (0)
Data not yet available
No reference posted for this study.